Subscribe
Models
Our Products
Featured Catalog
Humanized Mouse Models
Tool Mice
Custom Model Services
Preclinical Solutions
Resources
About Us
huSPAST-HA-R499H Mouse
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
huSPAST-HA-R499H Mouse
Product Name
huSPAST-HA-R499H Mouse
Product ID
C002144
Strain Name
C57BL/6Cya-Spasttm2(HA tag-hSPAST*R499H)/Cya
Background
C57BL/6Cya
Status
When using this mouse strain in a publication, please cite “huSPAST-HA-R499H Mouse (Catalog C002144) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
The standard delivery applies for a guaranteed minimum of three heterozygous carriers. Breeding services for homozygous carriers and/or specified sex are available.
+
Standard products are sold as live mice derived from cryorecovery or expansion. Frozen materials are available upon request. Pricing and lead times depend on real-time inventory.
Basic Information
Related Resource
Basic Information
Gene Name
SPAST
Gene Alias
FSP2, SPG4, ADPSP
NCBI ID
Chromosome
Chr 2 (Human)
MGI ID
Datasheet
Strain Description
Hereditary spastic paraplegia (HSP) is a hereditary neurodegenerative disease characterized pathologically by retrograde axonal degeneration of the corticospinal tract and the posterior columns of the spinal cord. Its clinical manifestations include progressive spastic weakness of both lower limbs, scissor gait, hyperreflexia, and positive pathological signs. The prevalence of autosomal dominant HSP is approximately 1–5 per 100,000, and it usually begins in young adulthood. SPG4, caused by mutations in the SPAST gene, is the most common autosomal dominant HSP subtype, accounting for about 40% of all autosomal dominant HSP families [1-3], and it is also the most common subtype in Chinese autosomal dominant HSP cohorts [4]. Spastin, encoded by SPAST, is a member of the AAA+ ATPase family. By severing microtubules, it regulates microtubule length, dynamics, and axonal transport, and is essential for maintaining cytoskeletal homeostasis in long axons [5]. SPAST mutations are predominantly missense, nonsense, and splice-site variants; whole-gene deletions can also cause the disease. Loss of function (haploinsufficiency) is the primary pathogenic mechanism. Decreased microtubule-severing activity leads to impaired axonal transport and distal axonal degeneration, ultimately resulting in progressive spastic paraplegia [3,6]. There is currently no disease-modifying therapy for SPG4; clinical management is mainly symptomatic treatment of spasticity.
The p.Arg499His (R499H) variant is a missense mutation in the SPAST gene caused by a nucleotide substitution at c.1496G>A (NM_014946.4), resulting in the replacement of arginine (Arg) with histidine (His) at amino acid position 499 of the Spastin protein. This variant is located within the AAA domain of Spastin and may affect its normal function. It has been reported in multiple clinical studies to be associated with hereditary spastic paraplegia type 4 (SPG4). Affected individuals may exhibit infantile-onset symptoms, including lower limb spasticity and delayed motor development. Some cases may also present with dystonia, dysarthria, and cognitive impairment [7-8].
huSPAST-HA-R499H mice were generated using gene-editing technology by replacing the sequence from the ATG start codon to the TAA stop codon of the mouse Spast gene with the sequence from the ATG start codon to the TAA stop codon of the human SPAST gene. The HA tag was inserted upstream of the human TAA stop codon, and the p.R499H (CGT to CAT) mutation was introduced into exon 13 of the human SPAST gene. This model can be used to investigate the pathogenesis of hereditary spastic paraplegia type 4 (SPG4) associated with the SPAST R499H mutation, as well as to support the development and efficacy evaluation of targeted therapeutics.
Reference
Salinas S, et al. Hereditary spastic paraplegia: clinical features and pathogenetic mechanisms. Lancet Neurol. 2008;7(12):1127-1138.
Ruano L, et al. The global epidemiology of hereditary ataxia and spastic paraplegia: a systematic review of prevalence studies. Neuroepidemiology. 2014;42(3):174-183.
Fonknechten N, et al. Spectrum of SPG4 mutations in autosomal dominant spastic paraplegia. Hum Mol Genet. 2000;9(4):637-644.
Zhao M, et al. Genetic and Clinical Profile of Chinese Patients with Autosomal Dominant Spastic Paraplegia. Mol Diagn Ther. 2019;23(6):781-789.
Roll-Mecak A, et al. Structural basis of microtubule severing by the hereditary spastic paraplegia protein spastin. Nature. 2008;451(7176):363-367.
Patrono C, et al. Missense and splice site mutations in SPG4 suggest loss-of-function in dominant spastic paraplegia. J Neurol. 2002;249(2):200-205.
Nan H, et al. A p.Arg499His mutation in SPAST is associated with infantile-onset complicated spastic paraplegia: a case report and review of the literature. BMC Neurol. 2021 Nov 9;21(1):439.
Mo A, et al. Early-Onset and Severe Complex Hereditary Spastic Paraplegia Caused by De Novo Variants in SPAST. Mov Disord. 2022 Dec;37(12):2440-2446.
Strain Strategy
The sequence from the ATG start codon to the TAA stop codon of the mouse Spast gene was replaced with the sequence from the ATG start codon to the TAA stop codon of the human SPAST gene. The HA tag was inserted upstream of the TAA stop codon of the human SPAST gene, and the p.R499H (CGT to CAT) mutation was introduced into human SPAST exon 13.

Figure 1. Gene editing strategy of huSPAST-HA-R499H mice.
Application Area
Research on the pathogenesis of hereditary spastic paraplegia type 4 (SPG4);
Screening, development, and preclinical in vivo evaluation of SPAST-targeted therapies.
Related Resource
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
